Home | All secondary_outcomes

[RDF data]
Secondary Outcomes #100323

Resource URI: http://static.linkedct.org/resource/secondary_outcomes/100323
PropertyValue
rdfs:label Secondary Outcomes #100323
linkedct:measure Safety & tolerability, pharmacokinetic assessments of Everolimus and Gemcitabine combination therapy in these patient populations. Phase II objective response rates (ORR), duration of response, progression-free survival (PFS), overall survival (OS)
linkedct:safety_issue No
is linkedct:secondary_outcomes of <http://static.linkedct.org/resource/trials/NCT00560963>
linkedct:secondary_outcomes_id 100323 (xsd:int)
linkedct:time_frame 36 weeks
rdf:type linkedct:secondary_outcomes